Rebecca Ramirez is a showrunner at NPR's Short Wave. With a diverse background in history and neuroscience, she explores themes in health and wellness, science, and alternative medicine, as well as topics like astronomy and AI. Her work has been featured in various outlets including Georgia Public Broadcasting, WBUR, and NPR.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Rebecca's coverage heavily leans towards scientific themes, with a focus on health, climate change, artificial intelligence, and space exploration. Her reliance on expert commentary and data suggests that she is likely to be responsive to pitches from experts in these fields.
Given her broad range of topics within the scientific domain, Rebecca may appreciate pitches that offer diverse perspectives or insights into cutting-edge research across different areas of science. She appears open to discussions around emerging trends in technology as well as human and environmental health.
While she has no specific geographic focus mentioned, since her articles are not limited by geography but rather by topic area (scientific), experts from any location who can provide valuable insights into these subjects could effectively reach out to her for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Rebecca Ramirez, Christopher Intagliata, Juana Summers, Emily Kwong, Ari Daniel, Berly McCoy, Jason Fuller
NPR Luke Rosedahl, Ph.D., and Isabella Cabaleiro, research lab specialist, participate in a virtual reality experiment examining how movement affects learning.
Math has created some of humanity's oldest intellectual challenges. And AI is completely changing the game. This year AI solved one of math’s most difficult problems. Since then, OpenAI published hundreds of new math results. So is this the end for the people who’ve dedicated their careers to pushing forward math? We get into it with NPR science correspondent Geoff Brumfel, who weighs the risks and rewards of AI’s math takeover.Interested in more technology and AI news? Email us your question at [email protected] public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org.
By: Geoff Brumfiel, Regina G. Barber, Rebecca Ramirez, Juan Diego Ramirez
Transcript [MUSIC PLAYING] EMILY KWONG: You're listening to Short Wave from NPR.
By: Elana Gordon
Famously, polls got the 2016 election wrong. And they’d been off for multiple elections since. So, Monday night, political scientist Jack Rametta nervously refreshed his Senate forecasting model for the final time. Would it be right this time? Or would it yet again cast doubt on whether modeling, statistics and forecasting can still help us understand what motivates people to vote? Now that the results are in, so is Jack – to tell us how he did, and what his and other researchers’ predictions tell us about the evolving science of polling and forecasting.Interested in more science behind the news? Email us your question at [email protected] public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org.
By: Rebecca Ramirez, Regina G. Barber, Elana Gordon
Transcript [MUSIC PLAYING] EMILY KWONG: You're listening to Short Wave from NPR.
By: Rebecca Ramirez, Emily Kwong, Elana Gordon
What's the latest on how GLP-1 medications affect pregnancy? J Studios/Getty Images hide caption The explosion of GLP-1 drugs has created a gray zone for pregnancy.
By: Emily Kwong, Rebecca Ramirez, Elana Gordon
Transcript EMILY KWONG: You're listening to Short Wave from NPR. How much do we understand about the impact of GLPs on pregnancy and reproductive health?
By: Hannah Chinn, Rebecca Ramirez, Nathan Rott
The Peruvian anchoveta is one of the most commercially important fish species in the world. But the industry could be upended by this year's super El Niño.
By: Nathan Rott, Hannah Chinn, Rebecca Ramirez
Transcript SPEAKER: You're listening to Short Wave from NPR. NATE ROTT: Hundreds of years ago-- it's hard to say exactly when-- fishermen in South America started to pick up on a trend.
Reversing aging may sound like science fiction, but scientists have already found a way to do it—at least, theoretically. Based on a 2012 Nobel-prize winning discovery, researchers are testing whether they can revert diseased cells in the eye back to young and healthy ones. They gave people a drug this year. If it works, it’ll open the door to curing and possibly preventing other age-related diseases. And that led producer Berly McCoy to wonder: Could all this research eventually extend our human lifespans? If you like this episode, check out our episodes on zombie cells, why our hair turns gray and why we die.Interested in more science on aging? Email us your question at [email protected] public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org.
